Abstract
Total hip arthroplasty (THA) is a highly effective intervention for hip osteoarthritis. The increasing demand for THA is driven by an expanding pool of eligible patients, including elderly individuals with comorbidities. Statins, which are widely used to reduce cardiovascular risk, have shown potential benefits in reducing postoperative complications after joint arthroplasty. This study aims to evaluate the influence of statin use on THA outcomes and postoperative quality of life (QOL). This retrospective observational cohort study was conducted at a single center. Patients who underwent primary THA between 2015 and 2021 were identified and categorized into the statin-exposed and non-statin cohorts. Patients were interviewed regarding postoperative complications and completed the Short Form-8 questionnaire to assess their QOL. Statistical analyses were performed using t tests, Chi-square tests, and correlation tests. In total, 364 patients were included in the final sample with 37 patients in the statin-exposed cohort. The statin-exposed cohort included significantly older patients with higher comorbidity rates. However, there were no significant differences in postoperative joint or systemic complications or readmission rates between the 2 cohorts. The in-hospital mortality was lower in the statin cohort, but the difference was not statistically significant (0% vs 8.9%, P = .059). There was no significant difference between the 2 cohorts based on the Short Form-8 questionnaire (21.65 ± 8.14 vs 20.16 ± 8.67, P = .310). Contrary to previous studies, this study did not find significant differences in THA outcomes and QOL between statin-exposed and non-statin cohorts. This disparity may be a result of differences in study design, patient populations, and the timing of statin initiation relative to surgery. The findings of this study should be validated through larger studies to assess the effects of statin use more firmly.